The triple agonist

The first metabolic peptides played a single note. A GLP-1 agonist activates one receptor — the GLP-1 receptor — and works through the cascade behind a single hormone’s biology. Then came the two-note version: tirzepatide engages both the GLP-1 and GIP receptors from one molecule. The newest step adds a third: retatrutide, an investigational peptide that activates GLP-1, GIP, and — the surprising one — the glucagon receptor, all at once.

The organizing idea is combination as physiology. Rather than push one pathway harder, these molecules recruit several arms of the metabolic system so their effects add up — a chord instead of a louder single note.

Glucagon is the hormone that raises blood sugar. It is insulin’s counterweight — released in fasting to pull glucose out of the liver. So putting a glucagon-receptor agonist into a drug meant to improve metabolic health looks, at first glance, exactly backwards.

The resolution is that glucagon does more than one thing. Alongside its effect on blood sugar, glucagon-receptor activation increases energy expenditure — the body burns more fuel. On its own, that comes packaged with the unwanted glucose-raising effect. But paired with two incretins that drive glucose-dependent insulin release and appetite reduction, the glucose-raising arm is held in check while the energy-expenditure arm is recruited. The incretins cover glucagon’s downside; glucagon adds a lever the incretins don’t have.

Adding receptors is not simply stacking benefits. Each pathway carries its own effects and its own liabilities, and the three receptors have to be engaged in the right proportion. A tri-agonist is tuned so that its potency at GLP-1, GIP, and glucagon sits in a deliberate ratio — enough glucagon signal to raise energy expenditure, enough incretin signal to keep glucose in line. Get the balance wrong and the glucose-raising arm wins. The engineering challenge isn’t hitting three targets; it’s balancing them.

Amplifying incretin signaling all at once is a large physiological change, and the body does not absorb it instantly. The same slowed-stomach-emptying mechanism that helps these molecules work is, early on, felt as nausea; the gut and its receptors need time to acclimate before the effect settles.

That is why these peptides are introduced gradually rather than at full strength — not an arbitrary rule but a reflection of real receptor adaptation. Signaling systems down-regulate and recalibrate when flooded; easing the system in lets that adaptation happen without overwhelming it. The ramp-up is biology, not bureaucracy.

Retatrutide is investigational — under study, not approved. In a mid-stage (phase 2) trial, the reductions in body weight were among the largest reported for this class, reaching roughly a quarter of body weight by 48 weeks in the most-exposed group. A large phase 3 program (TRIUMPH), enrolling thousands of participants over a longer horizon, is running now, with results anticipated around 2026.

Until those read out, the honest label is promising but unproven at scale — which is exactly why its entry in the catalog carries an Investigational badge rather than an established one.

Step back and the trajectory is clear. Peptide medicine began by replacing a missing hormone, moved to re-engineering a single signal for durability, and has now arrived at composing several signals into one molecule. The frontier is no longer a stronger agonist — it’s the right combination, in the right ratio, of the hormones the body already uses. The instrument didn’t get louder. It learned to play chords.